<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Concord Biotech Limited on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/concord-biotech-limited/</link>
    <description>Recent content in Concord Biotech Limited on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 21 Feb 2025 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/concord-biotech-limited/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Concord Biotech Limited: Q3 &amp; 9M FY25 Earnings Call</title>
      <link>https://reports.muthu.co/posts/concord-biotech-limited-q3--9m-fy25-earnings-call2025-02-21/</link>
      <pubDate>Fri, 21 Feb 2025 00:00:00 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/concord-biotech-limited-q3--9m-fy25-earnings-call2025-02-21/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;earnings-call-transcript-analysis-report&#34;&gt;&#xA;  Earnings Call Transcript Analysis Report&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#earnings-call-transcript-analysis-report&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;financial-performance&#34;&gt;&#xA;  Financial Performance&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-performance&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Revenue:&lt;/strong&gt; Q3 FY25 revenue stood at INR 244 crores compared to INR 240 crores in Q3 FY24, a 1% increase. 9 months FY25 revenue increased by 10% year-on-year to INR 770 crores (9 months FY24: INR 698 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA:&lt;/strong&gt; Q3 FY25 EBITDA stood at INR 98 crores with margins at 40.1%. EBITDA for 9 months FY25 stood at INR 315 crores, representing a growth of 6% year-on-year.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit After Tax (PAT):&lt;/strong&gt; Q3 FY25 PAT stood at INR 76 crores with margins at 31.1%. PAT for 9 months FY25 stood at INR 231 crores as compared to INR 213 crores in the same period last year, a growth of 9% Y-o-Y.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;API Revenue:&lt;/strong&gt; Q3 FY25 API revenues stood at INR 176 crores against INR 172 crores in Q3 last year, a growth of 3% year-on-year (9.6% including interunit sales). API revenue in the 9 months of this year stood at INR 577 crores against INR 562 crores during the same period last year.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Formulation Revenue:&lt;/strong&gt; Q3 FY25 Formulation segment stood at INR 67 crores. For 9 months FY25, revenues from the Formulation segment stood at INR 192 crores, up by 42% on a year-on-year basis.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Guidance:&lt;/strong&gt; Long-term guidance of achieving a 25% CAGR growth over the next 5 years is maintained.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Margins:&lt;/strong&gt; Long-term sustainable EBITDA margin guidance is in the range of 40% to 43%.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;strategic-initiatives--business-updates&#34;&gt;&#xA;  Strategic Initiatives &amp;amp; Business Updates&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#strategic-initiatives--business-updates&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Product Expansion:&lt;/strong&gt; Aim to introduce 8 to 10 additional products over the next 3 years, with a strong focus on oncology and anti-infectives.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;CDMO Business:&lt;/strong&gt; Seeing a growing number of inquiries and multiple RFQs being submitted. Now seen as a medium-term growth driver.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Investment in Palvella Therapeutics Inc.:&lt;/strong&gt; Strategic investment of $1 million in compulsory convertible notes to pave the way for a strategic partnership focused on the manufacturing and commercialization of QTORIN.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Investment in CleanMax Private Limited:&lt;/strong&gt; Acquiring a 26% equity stake in CleanMax to power Dholka plant with renewable energy.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Injectable Plant:&lt;/strong&gt; Scheduled to begin commercial production in the current quarter.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Sustainability:&lt;/strong&gt; Honored with the Sustainability Reporting Award from the Institute of Chartered Accountants of India.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;market--competitive-landscape&#34;&gt;&#xA;  Market &amp;amp; Competitive Landscape&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#market--competitive-landscape&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Formulation Business:&lt;/strong&gt; Gaining strong acceptance among customers across various regions.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Strategic Focus:&lt;/strong&gt; Target domestic and emerging markets, leveraging expertise and market reach with an opportunistic approach for the regulated markets.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Global Presence:&lt;/strong&gt; Goal to establish a strong global presence and achieve market leadership, targeting a sizeable global market share within the next 5 years.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;risk-factors--challenges&#34;&gt;&#xA;  Risk Factors &amp;amp; Challenges&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#risk-factors--challenges&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Customer Procurement Patterns:&lt;/strong&gt; &amp;ldquo;Customer procurement patterns may lead to lumpiness, with some quarters experiencing higher procurement than others.&amp;rdquo;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Calendar Year Closure:&lt;/strong&gt; Formulation segment revenues were impacted due to calendar year closure for many global clients.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;forward-looking-statements&#34;&gt;&#xA;  Forward-Looking Statements&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#forward-looking-statements&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Growth Outlook:&lt;/strong&gt; Positive outlook, in line with long-term guidance of achieving a 25% CAGR growth over the next 5 years.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Formulation Business Growth:&lt;/strong&gt; Anticipate substantial growth in both product offerings and customer acquisition in the Formulation business.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;CDMO Growth:&lt;/strong&gt; CDMO is now seen as a medium-term growth driver.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Injectable Plant Revenue:&lt;/strong&gt; Revenue generation from the injectable plant is expected to build up over the next financial year.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;qa-insights&#34;&gt;&#xA;  Q&amp;amp;A Insights&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#qa-insights&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Revenue Growth:&lt;/strong&gt; Analyst questioned if the current year growth guidance would be revised downward given the trailing 12-month revenues.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;CDMO:&lt;/strong&gt; Analyst questioned the CDMO contracts.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Capacity Utilization:&lt;/strong&gt; Questions regarding the capacity utilization of all facilities.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;management-tone--sentiment&#34;&gt;&#xA;  Management Tone &amp;amp; Sentiment&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#management-tone--sentiment&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Stable Performance:&lt;/strong&gt; Pleased to report stable performance for Q3 FY &amp;lsquo;25.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Positive Outlook:&lt;/strong&gt; Outlook remains positive, in line with long-term guidance.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Emphasis on Annual Assessment:&lt;/strong&gt; &amp;ldquo;I would still emphasize to assess our financial results on an annualized basis rather than a quarterly one.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&#xA;&#xA;&#xA;&lt;div class=&#34;button-container&#34;&gt;    &#xA;    &lt;a href=&#34;https://www.bseindia.com/xml-data/corpfiling/AttachHis/2331ef6f-b29f-45a9-8504-a240ea1b4f36.pdf&#34; target=&#34;_blank&#34; class=&#34;report-button&#34;&gt;&#xA;      &lt;i class=&#34;fas fa-file-pdf&#34;&gt;&lt;/i&gt; Download Transcript&#xA;    &lt;/a&gt;&#xA;&lt;/div&gt;</description>
    </item>
  </channel>
</rss>
